Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11 USD | -4.26% | -23.39% | +20.89% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.89% | 11.88M | |
+19.19% | 47.02B | |
+48.77% | 41.86B | |
+0.23% | 41.76B | |
-4.27% | 28.8B | |
+11.55% | 26.05B | |
-22.11% | 19.15B | |
+4.10% | 12.55B | |
+29.25% | 12.34B | |
-4.21% | 11.82B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier